This PWA model mimics a subtype of PCOS patients that exhibit chronic hyperandrogenism, with marked metabolic, hormonal, and reproductive/gonadal alterations, which represent the majority of cases
But a 'no' from Aetna is not necessarily the end of the road
Statins, ACE inhibitors, and the majority of cancer chemotherapies were advanced through pharmacologic and clinical reasoning rather than Mendelian genetics
Clinical studies have shown that GLP-1 medications may help support metabolic health during the menopause transition by improving metabolic stability and supporting blood sugar control
There isn't independent clinical data provided here confirming added benefit from these additions in this formulation, so treat it as a bonus rather than a proven feature
Furthermore, GLP-1 RAs have shown promise in reducing blood pressure, a crucial benefit given that high blood pressure can exacerbate both kidney and heart problems in diabetes